Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

18 Feb 2019

Abstract excerpt

BACKGROUND: Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted therapies for PeM exist. Some immune checkpoint inhibitor studies of mesothelioma have found positivity to be associated with a worse prognosis. METHODS: To search for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Myasthenia Gravis and Thymoma
Share to Occupational and environmental lung diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30777124
DOI: 10.1186/s13073-019-0620-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaPMID 30777124Read ↗

BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaSemantic proximity Read ↗

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic ResponseSemantic proximity Read ↗

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.Semantic proximity Read ↗

Inactivation of BAP1 and the Hippo Pathway Defines the Mutational Landscape of Peritoneal MesotheliomaSemantic proximity Read ↗

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaSemantic proximity Read ↗

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.Semantic proximity Read ↗

Isolated <i>BAP1</i> loss in malignant pleural mesothelioma predicts immunogenicity with implications for immunotherapeutic responseSemantic proximity Read ↗

Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular LandscapeSemantic proximity Read ↗

Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.Semantic proximity Read ↗

Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome SequencingSemantic proximity Read ↗

Genomic Landscape of Malignant Mesotheliomas.Semantic proximity Read ↗

Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.